Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation

by Stanton L. Gerson MD (Editor), Edmund C. Lattime (Editor), Stanton L. Gerson (Editor)

Overview

The Second Edition of Gene Therapy of Cancer provides crucial updates on the basic science and ongoing research in this field, examining the state of the art technology in gene therapy and its therapeutic applications to the treatment of cancer. The clinical chapters are improved to include new areas of research and more successful trials. Chapters emphasize the scientific basis of gene therapy using immune, oncogene, antisense, pro-drug activating, and drug resistance gene targets, while other chapters discuss therapeutic approaches and clinical applications. This book is a valuable reference for anyone needing to stay abreast of the latest advances in gene therapy treatment for cancer. - Provides in-depth description of targeted systems and treatment strategies - Explains the underlying cancer biology necessary for understanding a given therapeutic approach - Extensively covers immune therapeutics of vaccines, cytokines, and peptide-induced responses - Presents translational focus with emphasis on requirements for clinical implementation - Incorporates detailed illustrations of vectors and therapeutic approaches ideal for classroom presentations and general reference

Product Details

ISBN-13:	9780080491363
Publisher:	Elsevier Science & Technology Books
Publication date:	04/04/2002
Sold by:	Barnes & Noble
Format:	eBook
Pages:	534
File size:	12 MB
Note:	This product may take a few minutes to download.

About the Author

Stanton L Gerson is Director of the Case Comprehensive Cancer Center & the National Center for Regenerative Medicine at Case Western Reserve University and Director of University Hospitals Seidman Cancer Center in Cleveland. Dr. Gerson studies DNA repair, stem cells and cancer therapy. He showed that over-expression of the MGMT DNA repair gene could prevent cancer and that a mutant form of MGMT protects hematopoietic stem cells from chemotherapy using lentiviral gene therapy. He has interrogated MGMT, MMR and BER DNA repair pathways as targets for cancer therapy, and proposed that methoxyamine would block base excision repair used in combination with chemotherapy. Dr. Gerson also directed the initial use of mesenchymal stem cells (MSCs) in bone marrow transplantation & in gene therapy.
Edmund C. Lattime is Professor of Surgery at the Robert Wood Johnson Medical School and Deputy Director, The Cancer Institute of New Jersey. Dr. Lattime studies tumor immunology and immunotherapy focusing on the tumor-host interaction and the tumor microenvironment. While faculty at Sloan Kettering and then Thomas Jefferson University, his translational studies led to the development and Phase I testing of a novel Vaccinia-GMCSF construct designed to enhance the development of antitumor immunity via infection/transfection of the tumor microenvironment. Based on his mechanistic studies of immune escape mechanisms, his group recently developed and is testing a poxvirus-based immunization strategy, which uses antigen encoding poxvirus delivered to the tumor microenvironment, in patients with locally-advanced pancreatic cancer.
Stanton L. Gerson received his M.D. at Harvard Medical School. He was a Resident in Medicine at the Hospital of the University of Pennsylvania, where he became a Fellow in Hematology-Oncology in 1980. He is an Edward Mallinckrodt Jr. Foundation Scholar, and is currently Chief, Division of Hematology/Oncology at Case Western Reserve Univeristy, where he has served since 1983. Dr. Gerson is a member of several major professional and scientific societies and is a principal investigator of funded grants for several philanthropic organizations. He is author or a contributor to over 200 research papers, abstracts, theses and book chapters. Since 1987, Dr. Gerson has been invited to be a guest lecturer at over 40 national and international conferences.

Read an Excerpt

An invaluable reference to this rapidly expanding field

Table of Contents

Part I Vectors for Gene Therapy of Cancer1. Retroviral Vector Design for Cancer Gene TherapyI. IntroductionII. Applications for Retroviral Vectors in OncologyIII. Biology of RetrovirusesIV. Principles of Retroviral Vector SystemsV. Advances in Retroviral Vector TailoringVI. OutlookReferences2. Noninfectious Gene Transfer and Expression Systems for Cancer Gene TherapyI. IntroductionII. Advantages and Disadvantages of Infectious, Viral-Based Vectors for Human Gene TherapyIII. Rationale for Considering Noninfectious, Plasmid-Based Expression SystemsIV. Gene Transfer Technologies for Plasmid-Based Vectors: Preclinical Models and Clinical Cancer Gene Therapy TrialsV. Plasmid Expression VectorsVI. Future DirectionsReferences3. Parvovirus Vectors for the Gene Therapy of CancerI. IntroductionII. Biology of Parvoviridae and Vector DevelopmentIII. Applications of Recombinant Parvovirus Vectors to Cancer Gene TherapyIV. Perspectives, Problems, and Future ConsiderationsReferences4. Antibody-Targeted Gene TherapyI. IntroductionII. Background: Monoclonal Antibodies and Cancer TherapyIII. Recent Advances: Monoclonal-Antibody-Mediated Targeting and Cancer Gene TherapyIV. Future DirectionsReferences5. Ribozymes in Cancer Gene TherapyI. Introduction II. Ribozyme Structures and FunctionsIII. Cancer Disease Models for Ribozyme ApplicationIV. Challenges and Future DirectionsReferences6. The Advent of Lentiviral Vectors: Prospects for Cancer TherapyI. IntroductionII. Structure and Function of Lentiviruses III. Features that Distinguish Lentiviral from Oncoretroviral VectorsIV. Manufacture of Lentiviral VectorsV. Possible Applications of Lentiviral Vectors in Cancer TherapyVI. ConclusionsReferencesPart II Immune Targeted Gene Therapy7. Immunologic Targets for the Gene Therapy of CancerI. IntroductionII. Cellular (T-Lymphocyte-Mediated) Versus Humoral (Antibody-Mediated) Immune Responses to Tumor CellsIII. Response of CD4+ and CD8+ T Lymphocytes to Tumor Antigens Presented in the Context of Molecules Encoded by the Major Histocompatibility ComplexIV. Response of Tumor-Bearing Individuals to Tumor AntigensV. Tumor-Associated Peptides as Candidate Targets for Tumor-Specific LymphocytesVI. Immunotherapeutic Strategies for the Treatment of CancerVII.ConclusionsReferencesPart IIa Vaccine Strategies8. Development of Epitope-Specific Immunotherapies for Human Malignancies and Premalignant Lesions Expressing Mutated ras GenesI. IntroductionII. Cellular Immune Response and Antigen RecognitionIII. Pathways of Antigen Processing, Presentation, and Epitope ExpressionIV. T-Lymphocyte SubsetsV. ras Oncogenes in Neoplastic DevelopmentVI. Cellular Immune Responses Induced by ras Oncogene PeptidesVII. Identification of Mutant ras CD4+ and CD8+ T-Cell Epitopes Reflecting Codon 12 MutationsVIII. Anti-ras Immune System Interactions: Implications for Tumor Immunity and Tumor EscapeIX. Paradigm for Anti-ras Immune System Interactions in Cancer ImmunotherapyX. Future DirectionsReferencesPart IIb Dendritic Cell-Based Gene Therapy9. Introduction to Dendritic CellsI. IntroductionII. Features of Dendritic CellsIII. Dendritic Cell SubsetsIV. Functional Heterogeneity of Dendritic Cell SubsetsV. Dendritic Cells in Tumor ImmunologyVI. Dendritic Cells and Gene Therapy VII. ConclusionsReferences10. DNA and Dendritic Cell-Based Genetic Immunization Against CancerI. IntroductionII. BackgroundIII. Recent Advances: Methods of Genetic ImmunizationIV. Preclinical Development and Translation to the ClinicV. Proposed and Current Clinical TrialsVI. Future DirectionsReferences11. RNA-Transfected Dendritic Cells as ImmunogensI. IntroductionII. Advantages of Loading Dendritic Cells with Genetic MaterialIII. Viral Versus Nonviral Methods of Gene Transfer 200IV. RNA Versus DNA Loading of Dendritic CellsV. RNA Loading of Dendritic CellsVI. Amplification of RNA Used to Load Dendritic CellsVII. Uses of RNA-Loaded Dendritic CellsVIII. Future DirectionsReferencesPART IIc CYTOKINES AND CO-FACTORS12.

What People are Saying About This

From the Publisher

An invaluable reference to this rapidly expanding field

Editorial Reviews

The recently published book Gene Therapy of Cancer presents an excellent, detailed, and comprehensive review of the many therapeutic approaches currently under investigation, their underlying rationale, and areas for further development.
— CELL

Daniel A. Haber

...represents the 'state-of-the-art', describing the progress made to date in its written chapters. ...this book is a worthy addition to the laboratories and libraries serving the students, fellows and experienced researchers devoted to translating cancer gene therapy applications from laboratory to the bedside.

Robert E. Sobol

This is a textbook of the gene therapy of cancer. The purpose is to provide a comprehensive review of the basis and approaches involved in the gene therapy of cancer. The authors are successful in devising an easily read textbook for gene therapy that provides a basic understanding of retroviral vectors and their clinical application. It is relatively comprehensive in its appropriate initial orientation to gene therapy, without the in-depth biology found in some molecular biology textbooks. "The audience is physicians, students, nurses, and researchers interested in gene therapy and its clinical application in cancers. The book is written by credible investigators in the field and it fulfills its objectives. "This book has multiple black-and-white and color illustrations and figures to help clarify points within the text. The references to each chapter are generally extensive in providing further resource materials. Although the book lacks the in-depth character of a molecular biology textbook, it provides an excellent orientation and thought-provoking analysis of the field of gene therapy as it pertains to cancer. "This is a well-written book that is well worth the time of investigators interested in understanding the field of gene therapy in relation to medical oncology.

Richard K. Burt

Covers all modalities currently being used by developmental theorists to design new targeted treatments for cancer. Includes the basic biology of cancer and cancer immunology, along with cancer targets, oncogenes, the cell cycle, induction of apoptosis, drug resistance pathways, and tumor specific antigens. Includes discussions of therapies including gene replacement, ribozyme and antisense ligonucleotide therapy, retrovirus-mediated gene transfer, adenovirus gene transfer, nonviral approaches, tumor vaccines, engineered immunocompetent cells, and cytokine gene therapy. Annotation c. by Book News, Inc., Portland, Or.

Booknews

This second edition of a reference for researchers and clinicians provides updated information on the basic and applied sciences of gene therapy, covering areas including suicide gene therapy, oncogene and suppressor gene targeting, and the genetic modification of stem cells. Detailed background is given to explain the underlying cancer biology necessary to understand therapeutic approaches, and targeting systems and treatment strategies are explained. Material is in sections on vectors for gene therapy of cancer, immune targeted gene therapy, oncogene targeted gene therapy, manipulation of drug resistance mechanisms by gene therapy, antiangiogenesis and pro-apoptotic gene therapy, and prodrug activation strategies for gene therapy of cancer. The book is useful for researchers at all levels. Lattime is affiliated with The Cancer Institute of New Jersey. Gerson is affiliated with the Comprehensive Cancer Center of University Hospitals of Cleveland. Annotation c. Book News, Inc., Portland, OR (booknews.com)

" ...represents the 'state-of-the-art', describing the progress made to date in its written chapters. ...this book is a worthy addition to the laboratories and libraries serving the students, fellows and experienced researchers devoted to translating cancer gene therapy applications from laboratory to the bedside." —Robert E. Sobol, GenStar Therapeutics, Sidney Kimmel Cancer Center (2002)

From the Publisher